Karin Meyer, ny VD för CTR

Karin Meyer blir ny VD för Center for Translational Research Sweden AB (CTR)


CTR tillkännager att styrelsen har utsett Karin Meyer till ny verkställande direktör. Karin Meyer efterträder Mats Lindquist som varit verkställande direktör sedan starten av CTR 2016. Karin Meyer har en lång erfarenhet av ledande befattningar inom läkemedels- och biotechindustrin, god branschkännedom och en mycket god förståelse för utveckling av nya produkter inom dessa områden. Karin, … Continue reading Karin Meyer blir ny VD för Center for Translational Research Sweden AB (CTR)

New senior consultant: Emil Schwan


Welcome to RegSmart, Emil Schwan, senior consultant! Our new senior consultant Emil is a pharmacist with experience from performing GMP and GDP inspections, formulation development, manufacturing of medicinal products and pharmaceutical quality systems. He has been chief designer for several types of medicinal products. Most recently Emil comes from the Swedish Medical Products Agency, where … Continue reading New senior consultant: Emil Schwan

Ira Palminger Hallén

New senior consultant: Ira Palminger Hallén


We are happy to welcome Ira Palminger Hallén to RegSmart! Ira has over ten years’ experience as a regulatory expert covering nonclinical and clinical drug development. She has been a nonclinical assessor at the Swedish Medical Product Agency (MPA) reviewing toxicological/pharmacological documentation in drug applications from early development to market approval. Furthermore, Ira was Clinical … Continue reading New senior consultant: Ira Palminger Hallén

Can regulators keep up with innovation?


New technology has increased the understanding of disease mechanisms and enabled approval of products targeting small but specific patient populations; sometimes referred to as precision medicine. Gene- and cell therapies have reached the market, exemplified by CAR-T cells, and the research pipeline is promising. In addition, the medical device field is constantly growing creating new … Continue reading Can regulators keep up with innovation?